Sarepta Therapeutics Restructuring

Order byBest matchMost fresh

Sarepta, Restructuring Plan

Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan

Shares of struggling drug developer Sarepta Therapeutics ( SRPT) skyrocketed nearly 40% in extended trading Wednesday after the company unveiled a major restructuring plan.

· 3d · on MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

· 3d · on MSN

Sarepta Therapeutics to Restructure, Lay Off 500 Workers

· 1d

Sarepta tells FDA it won’t halt shipments despite patient deaths

Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient r...

· 1d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

· 1d

Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says

FDA asks Sarepta to stop shipping gene therapy

Digest more

GEN - Genetic Engineering and Biotechnology News · 3d

Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the deaths of two Duchenne muscular dystrophy (DMD) patients following treatment with the marketed gene therapy Elevidys® (delandistrogene moxeparvovec-rokl).

· 1d · on MSN

Patient Deaths Linked to Sarepta Gene Therapy Prompt FDA Probe

· 13h · on MSN

Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request

Hoodline3h

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Business Wire3d

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan

1don MSN

Gene-therapy company to eliminate 21 Durham employees as part of major restructuring

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an effort to cut annual operating costs by hundreds of millions of dollars.

Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its outlook. Click for my SRPT stock update.